 |
PDBsum entry 1cu1
 |
|
|
 |
 |
 |
 |
Enzyme class 1:
|
 |
E.C.2.7.7.48
- RNA-directed Rna polymerase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
RNA(n) + a ribonucleoside 5'-triphosphate = RNA(n+1) + diphosphate
|
 |
 |
 |
 |
 |
RNA(n)
|
+
|
ribonucleoside 5'-triphosphate
|
=
|
RNA(n+1)
Bound ligand (Het Group name = )
matches with 55.56% similarity
|
+
|
diphosphate
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 2:
|
 |
E.C.3.4.21.98
- hepacivirin.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Hydrolysis of four peptide bonds in the viral precursor polyprotein, commonly with Asp or Glu in the P6 position, Cys or Thr in P1 and Ser or Ala in P1'.
|
 |
 |
 |
 |
 |
Enzyme class 3:
|
 |
E.C.3.4.22.-
- ?????
|
|
 |
 |
 |
 |
 |
Enzyme class 4:
|
 |
E.C.3.6.1.15
- nucleoside-triphosphate phosphatase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
a ribonucleoside 5'-triphosphate + H2O = a ribonucleoside 5'-diphosphate + phosphate + H+
|
 |
 |
 |
 |
 |
ribonucleoside 5'-triphosphate
|
+
|
H2O
|
=
|
ribonucleoside 5'-diphosphate
|
+
|
phosphate
|
+
|
H(+)
Bound ligand (Het Group name = )
corresponds exactly
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 5:
|
 |
E.C.3.6.4.13
- Rna helicase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
ATP + H2O = ADP + phosphate + H+
|
 |
 |
 |
 |
 |
ATP
|
+
|
H2O
|
=
|
ADP
|
+
|
phosphate
|
+
|
H(+)
Bound ligand (Het Group name = )
corresponds exactly
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Structure
7:1353-1363
(1999)
|
|
PubMed id:
|
|
|
|
|
| |
|
Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase.
|
|
N.Yao,
P.Reichert,
S.S.Taremi,
W.W.Prosise,
P.C.Weber.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
BACKGROUND: Hepatitis C virus (HCV) currently infects approximately 3% of the
world's population. HCV RNA is translated into a polyprotein that during
maturation is cleaved into functional components. One component, nonstructural
protein 3 (NS3), is a 631-residue bifunctional enzyme with protease and helicase
activities. The NS3 serine protease processes the HCV polyprotein by both cis
and trans mechanisms. The structural aspects of cis processing, the
autoproteolysis step whereby the protease releases itself from the polyprotein,
have not been characterized. The structural basis for inclusion of protease and
helicase activities in a single polypeptide is also unknown. RESULTS: We report
here the 2.5 A resolution structure of an engineered molecule containing the
complete NS3 sequence and the protease activation domain of nonstructural
protein 4A (NS4A) in a single polypeptide chain (single chain or scNS3-NS4A). In
the molecule, the helicase and protease domains are segregated and connected by
a single strand. The helicase necleoside triphosphate and RNA interaction sites
are exposed to solvent. The protease active site of scNS3-NS4A is occupied by
the NS3 C terminus, which is part of the helicase domain. Thus, the
intramolecular complex shows one product of NS3-mediated cleavage at the
NS3-NS4A junction of the HCV polyprotein bound at the protease active site.
CONCLUSIONS: The scNS3-NS4A structure provides the first atomic view of
polyprotein cis processing. Both local and global structural rearrangements
follow the cis cleavage reaction, and large segments of the polyprotein can be
folded prior to proteolytic processing. That the product complex of the cis
cleavage reaction exists in a stable molecular conformation suggests
autoinhibition and substrate-induced activation mechanisms for regulation of NS3
protease activity.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
Figure 8.
Figure 8. HCV polyprotein processing in the nonstructural
region. Nonstructural proteins NS3, NS4A, NS4B, NS5A and NS5B
are colored purple, red, green, pink and orange, respectively.
(a) Attachment of the 1984-residue polyprotein to the membrane.
(b) NS4A activation and folding of the NS3 N terminus. (c)
Subsequent cleavage reactions. To highlight the fact that the
sequence of cleavage reactions has not been firmly established,
the N terminus of the polyprotein substrate is dotted and the
schematic diagrams are enclosed in a box. (d) The release of
NS4B and NS5A and formation of the replication complex core.
|
 |
|
|
|
| |
The above figure is
reprinted
by permission from Cell Press:
Structure
(1999,
7,
1353-1363)
copyright 1999.
|
|
| |
Figure was
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
K.Morikawa,
C.M.Lange,
J.Gouttenoire,
E.Meylan,
V.Brass,
F.Penin,
and
D.Moradpour
(2011).
Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus.
|
| |
J Viral Hepat,
18,
305-315.
|
 |
|
|
|
|
 |
M.Geitmann,
G.Dahl,
and
U.H.Danielson
(2011).
Mechanistic and kinetic characterization of hepatitis C virus NS3 protein interactions with NS4A and protease inhibitors.
|
| |
J Mol Recognit,
24,
60-70.
|
 |
|
|
|
|
 |
S.A.Shiryaev,
A.V.Chernov,
T.N.Shiryaeva,
A.E.Aleshin,
and
A.Y.Strongin
(2011).
The acidic sequence of the NS4A cofactor regulates ATP hydrolysis by the HCV NS3 helicase.
|
| |
Arch Virol,
156,
313-318.
|
 |
|
|
|
|
 |
T.Shimakami,
C.Welsch,
D.Yamane,
D.R.McGivern,
M.Yi,
S.Zeuzem,
and
S.M.Lemon
(2011).
Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus.
|
| |
Gastroenterology,
140,
667-675.
|
 |
|
|
|
|
 |
C.A.Belon,
Y.D.High,
T.I.Lin,
F.Pauwels,
and
D.N.Frick
(2010).
Mechanism and specificity of a symmetrical benzimidazolephenylcarboxamide helicase inhibitor.
|
| |
Biochemistry,
49,
1822-1832.
|
 |
|
|
|
|
 |
D.N.Frick,
O.Ginzburg,
and
A.M.Lam
(2010).
A method to simultaneously monitor hepatitis C virus NS3 helicase and protease activities.
|
| |
Methods Mol Biol,
587,
223-233.
|
 |
|
|
|
|
 |
M.Gu,
and
C.M.Rice
(2010).
Three conformational snapshots of the hepatitis C virus NS3 helicase reveal a ratchet translocation mechanism.
|
| |
Proc Natl Acad Sci U S A,
107,
521-528.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
C.A.Belon,
and
D.N.Frick
(2009).
Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C.
|
| |
Future Virol,
4,
277-293.
|
 |
|
|
|
|
 |
H.Tang,
and
H.Grisé
(2009).
Cellular and molecular biology of HCV infection and hepatitis.
|
| |
Clin Sci (Lond),
117,
49-65.
|
 |
|
|
|
|
 |
M.Krawczyk,
M.Wasowska-Lukawska,
I.Oszczapowicz,
and
A.M.Boguszewska-Chachulska
(2009).
Amidinoanthracyclines - a new group of potential anti-hepatitis C virus compounds.
|
| |
Biol Chem,
390,
351-360.
|
 |
|
|
|
|
 |
R.Assenberg,
E.Mastrangelo,
T.S.Walter,
A.Verma,
M.Milani,
R.J.Owens,
D.I.Stuart,
J.M.Grimes,
and
E.J.Mancini
(2009).
Crystal structure of a novel conformational state of the flavivirus NS3 protein: implications for polyprotein processing and viral replication.
|
| |
J Virol,
83,
12895-12906.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
T.A.Jennings,
S.G.Mackintosh,
M.K.Harrison,
D.Sikora,
B.Sikora,
B.Dave,
A.J.Tackett,
C.E.Cameron,
and
K.D.Raney
(2009).
NS3 helicase from the hepatitis C virus can function as a monomer or oligomer depending on enzyme and substrate concentrations.
|
| |
J Biol Chem,
284,
4806-4814.
|
 |
|
|
|
|
 |
T.Phan,
R.K.Beran,
C.Peters,
I.C.Lorenz,
and
B.D.Lindenbach
(2009).
Hepatitis C virus NS2 protein contributes to virus particle assembly via opposing epistatic interactions with the E1-E2 glycoprotein and NS3-NS4A enzyme complexes.
|
| |
J Virol,
83,
8379-8395.
|
 |
|
|
|
|
 |
T.Shimakami,
R.E.Lanford,
and
S.M.Lemon
(2009).
Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities.
|
| |
Curr Opin Pharmacol,
9,
537-544.
|
 |
|
|
|
|
 |
V.Serebrov,
R.K.Beran,
and
A.M.Pyle
(2009).
Establishing a mechanistic basis for the large kinetic steps of the NS3 helicase.
|
| |
J Biol Chem,
284,
2512-2521.
|
 |
|
|
|
|
 |
B.Sikora,
Y.Chen,
C.F.Lichti,
M.K.Harrison,
T.A.Jennings,
Y.Tang,
A.J.Tackett,
J.B.Jordan,
J.Sakon,
C.E.Cameron,
and
K.D.Raney
(2008).
Hepatitis C virus NS3 helicase forms oligomeric structures that exhibit optimal DNA unwinding activity in vitro.
|
| |
J Biol Chem,
283,
11516-11525.
|
 |
|
|
|
|
 |
D.Luo,
T.Xu,
C.Hunke,
G.Grüber,
S.G.Vasudevan,
and
J.Lescar
(2008).
Crystal structure of the NS3 protease-helicase from dengue virus.
|
| |
J Virol,
82,
173-183.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.Lara,
R.M.Wohlhueter,
Z.Dimitrova,
and
Y.E.Khudyakov
(2008).
Artificial neural network for prediction of antigenic activity for a major conformational epitope in the hepatitis C virus NS3 protein.
|
| |
Bioinformatics,
24,
1858-1864.
|
 |
|
|
|
|
 |
N.A.Cannon,
M.J.Donlin,
X.Fan,
R.Aurora,
and
J.E.Tavis
(2008).
Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy.
|
| |
PLoS ONE,
3,
e2123.
|
 |
|
|
|
|
 |
P.Halfon,
M.Bourlière,
H.Khiri,
G.Pénaranda,
A.Martineau,
V.Oulès,
J.Courcambeck,
and
P.Philibert
(2008).
Mutation rate in hepatitis C virus NS3 protease is not influenced by HIV-1 protease inhibitor therapy.
|
| |
AIDS,
22,
1694-1696.
|
 |
|
|
|
|
 |
R.K.Beran,
and
A.M.Pyle
(2008).
Hepatitis C Viral NS3-4A Protease Activity Is Enhanced by the NS3 Helicase.
|
| |
J Biol Chem,
283,
29929-29937.
|
 |
|
|
|
|
 |
V.Arumugaswami,
R.Remenyi,
V.Kanagavel,
E.Y.Sue,
T.Ngoc Ho,
C.Liu,
V.Fontanes,
A.Dasgupta,
and
R.Sun
(2008).
High-resolution functional profiling of hepatitis C virus genome.
|
| |
PLoS Pathog,
4,
e1000182.
|
 |
|
|
|
|
 |
V.Brass,
J.M.Berke,
R.Montserret,
H.E.Blum,
F.Penin,
and
D.Moradpour
(2008).
Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex.
|
| |
Proc Natl Acad Sci U S A,
105,
14545-14550.
|
 |
|
|
|
|
 |
W.Yang,
Y.Zhao,
J.Fabrycki,
X.Hou,
X.Nie,
A.Sanchez,
A.Phadke,
M.Deshpande,
A.Agarwal,
and
M.Huang
(2008).
Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no cross-resistance to NS3 protease and NS5B polymerase inhibitors.
|
| |
Antimicrob Agents Chemother,
52,
2043-2052.
|
 |
|
|
|
|
 |
Y.Ma,
J.Yates,
Y.Liang,
S.M.Lemon,
and
M.Yi
(2008).
NS3 helicase domains involved in infectious intracellular hepatitis C virus particle assembly.
|
| |
J Virol,
82,
7624-7639.
|
 |
|
|
|
|
 |
B.D.Lindenbach,
B.M.Prágai,
R.Montserret,
R.K.Beran,
A.M.Pyle,
F.Penin,
and
C.M.Rice
(2007).
The C terminus of hepatitis C virus NS4A encodes an electrostatic switch that regulates NS5A hyperphosphorylation and viral replication.
|
| |
J Virol,
81,
8905-8918.
|
 |
|
|
|
|
 |
C.L.Johnson,
D.M.Owen,
and
M.Gale
(2007).
Functional and therapeutic analysis of hepatitis C virus NS3.4A protease control of antiviral immune defense.
|
| |
J Biol Chem,
282,
10792-10803.
|
 |
|
|
|
|
 |
D.Moradpour,
F.Penin,
and
C.M.Rice
(2007).
Replication of hepatitis C virus.
|
| |
Nat Rev Microbiol,
5,
453-463.
|
 |
|
|
|
|
 |
D.N.Frick,
S.Banik,
and
R.S.Rypma
(2007).
Role of divalent metal cations in ATP hydrolysis catalyzed by the hepatitis C virus NS3 helicase: magnesium provides a bridge for ATP to fuel unwinding.
|
| |
J Mol Biol,
365,
1017-1032.
|
 |
|
|
|
|
 |
G.Dahl,
A.Sandström,
E.Akerblom,
and
U.H.Danielson
(2007).
Effects on protease inhibition by modifying of helicase residues in hepatitis C virus nonstructural protein 3.
|
| |
FEBS J,
274,
5979-5986.
|
 |
|
|
|
|
 |
G.Wen,
C.Chen,
X.Luo,
Y.Wang,
C.Zhang,
and
Z.Pan
(2007).
Identification and characterization of the NTPase activity of classical swine fever virus (CSFV) nonstructural protein 3 (NS3) expressed in bacteria.
|
| |
Arch Virol,
152,
1565-1573.
|
 |
|
|
|
|
 |
R.De Francesco,
and
A.Carfí
(2007).
Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus.
|
| |
Adv Drug Deliv Rev,
59,
1242-1262.
|
 |
|
|
|
|
 |
R.K.Beran,
V.Serebrov,
and
A.M.Pyle
(2007).
The serine protease domain of hepatitis C viral NS3 activates RNA helicase activity by promoting the binding of RNA substrate.
|
| |
J Biol Chem,
282,
34913-34920.
|
 |
|
|
|
|
 |
T.L.Tellinghuisen,
M.J.Evans,
T.von Hahn,
S.You,
and
C.M.Rice
(2007).
Studying hepatitis C virus: making the best of a bad virus.
|
| |
J Virol,
81,
8853-8867.
|
 |
|
|
|
|
 |
W.Zheng,
J.C.Liao,
B.R.Brooks,
and
S.Doniach
(2007).
Toward the mechanism of dynamical couplings and translocation in hepatitis C virus NS3 helicase using elastic network model.
|
| |
Proteins,
67,
886-896.
|
 |
|
|
|
|
 |
A.Lulla,
V.Lulla,
K.Tints,
T.Ahola,
and
A.Merits
(2006).
Molecular determinants of substrate specificity for Semliki Forest virus nonstructural protease.
|
| |
J Virol,
80,
5413-5422.
|
 |
|
|
|
|
 |
M.Yi,
X.Tong,
A.Skelton,
R.Chase,
T.Chen,
A.Prongay,
S.L.Bogen,
A.K.Saksena,
F.G.Njoroge,
R.L.Veselenak,
R.B.Pyles,
N.Bourne,
B.A.Malcolm,
and
S.M.Lemon
(2006).
Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations.
|
| |
J Biol Chem,
281,
8205-8215.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
N.Appel,
T.Schaller,
F.Penin,
and
R.Bartenschlager
(2006).
From structure to function: new insights into hepatitis C virus RNA replication.
|
| |
J Biol Chem,
281,
9833-9836.
|
 |
|
|
|
|
 |
P.O.Johansson,
M.Bäck,
I.Kvarnström,
K.Jansson,
L.Vrang,
E.Hamelink,
A.Hallberg,
A.Rosenquist,
and
B.Samuelsson
(2006).
Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
|
| |
Bioorg Med Chem,
14,
5136-5151.
|
 |
|
|
|
|
 |
R.J.Johnson,
S.R.Lin,
and
R.T.Raines
(2006).
A ribonuclease zymogen activated by the NS3 protease of the hepatitis C virus.
|
| |
FEBS J,
273,
5457-5465.
|
 |
|
|
|
|
 |
S.G.Mackintosh,
J.Z.Lu,
J.B.Jordan,
M.K.Harrison,
B.Sikora,
S.D.Sharma,
C.E.Cameron,
K.D.Raney,
and
J.Sakon
(2006).
Structural and biological identification of residues on the surface of NS3 helicase required for optimal replication of the hepatitis C virus.
|
| |
J Biol Chem,
281,
3528-3535.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
U.Kulkarni-Kale,
S.G.Bhosle,
G.S.Manjari,
M.Joshi,
S.Bansode,
and
A.S.Kolaskar
(2006).
Curation of viral genomes: challenges, applications and the way forward.
|
| |
BMC Bioinformatics,
7,
S12.
|
 |
|
|
|
|
 |
Y.Ding,
and
D.Wilkins
(2006).
Improving the Performance of SVM-RFE to Select Genes in Microarray Data.
|
| |
BMC Bioinformatics,
7,
S12.
|
 |
|
|
|
|
 |
C.Lin,
C.A.Gates,
B.G.Rao,
D.L.Brennan,
J.R.Fulghum,
Y.P.Luong,
J.D.Frantz,
K.Lin,
S.Ma,
Y.Y.Wei,
R.B.Perni,
and
A.D.Kwong
(2005).
In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.
|
| |
J Biol Chem,
280,
36784-36791.
|
 |
|
|
|
|
 |
C.Yon,
T.Teramoto,
N.Mueller,
J.Phelan,
V.K.Ganesh,
K.H.Murthy,
and
R.Padmanabhan
(2005).
Modulation of the nucleoside triphosphatase/RNA helicase and 5'-RNA triphosphatase activities of Dengue virus type 2 nonstructural protein 3 (NS3) by interaction with NS5, the RNA-dependent RNA polymerase.
|
| |
J Biol Chem,
280,
27412-27419.
|
 |
|
|
|
|
 |
G.Marceau,
P.Lapierre,
K.Béland,
H.Soudeyns,
and
F.Alvarez
(2005).
LKM1 autoantibodies in chronic hepatitis C infection: a case of molecular mimicry?
|
| |
Hepatology,
42,
675-682.
|
 |
|
|
|
|
 |
J.C.Ferreon,
A.C.Ferreon,
K.Li,
and
S.M.Lemon
(2005).
Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3/4A protease.
|
| |
J Biol Chem,
280,
20483-20492.
|
 |
|
|
|
|
 |
J.Wu,
A.K.Bera,
R.J.Kuhn,
and
J.L.Smith
(2005).
Structure of the Flavivirus helicase: implications for catalytic activity, protein interactions, and proteolytic processing.
|
| |
J Virol,
79,
10268-10277.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
N.L.Korneeva,
E.A.First,
C.A.Benoit,
and
R.E.Rhoads
(2005).
Interaction between the NH2-terminal domain of eIF4A and the central domain of eIF4G modulates RNA-stimulated ATPase activity.
|
| |
J Biol Chem,
280,
1872-1881.
|
 |
|
|
|
|
 |
C.Lin,
K.Lin,
Y.P.Luong,
B.G.Rao,
Y.Y.Wei,
D.L.Brennan,
J.R.Fulghum,
H.M.Hsiao,
S.Ma,
J.P.Maxwell,
K.M.Cottrell,
R.B.Perni,
C.A.Gates,
and
A.D.Kwong
(2004).
In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms.
|
| |
J Biol Chem,
279,
17508-17514.
|
 |
|
|
|
|
 |
D.Moradpour,
and
H.E.Blum
(2004).
A primer on the molecular virology of hepatitis C.
|
| |
Liver Int,
24,
519-525.
|
 |
|
|
|
|
 |
D.N.Frick,
R.S.Rypma,
A.M.Lam,
and
B.Gu
(2004).
The nonstructural protein 3 protease/helicase requires an intact protease domain to unwind duplex RNA efficiently.
|
| |
J Biol Chem,
279,
1269-1280.
|
 |
|
|
|
|
 |
D.N.Frick,
R.S.Rypma,
A.M.Lam,
and
C.M.Frenz
(2004).
Electrostatic analysis of the hepatitis C virus NS3 helicase reveals both active and allosteric site locations.
|
| |
Nucleic Acids Res,
32,
5519-5528.
|
 |
|
|
|
|
 |
F.Nishikawa,
K.Funaji,
K.Fukuda,
and
S.Nishikawa
(2004).
In vitro selection of RNA aptamers against the HCV NS3 helicase domain.
|
| |
Oligonucleotides,
14,
114-129.
|
 |
|
|
|
|
 |
M.K.Levin,
Y.H.Wang,
and
S.S.Patel
(2004).
The functional interaction of the hepatitis C virus helicase molecules is responsible for unwinding processivity.
|
| |
J Biol Chem,
279,
26005-26012.
|
 |
|
|
|
|
 |
V.Brass,
H.E.Blum,
and
D.Moradpour
(2004).
Recent developments in target identification against hepatitis C virus.
|
| |
Expert Opin Ther Targets,
8,
295-307.
|
 |
|
|
|
|
 |
A.M.Lam,
D.Keeney,
and
D.N.Frick
(2003).
Two novel conserved motifs in the hepatitis C virus NS3 protein critical for helicase action.
|
| |
J Biol Chem,
278,
44514-44524.
|
 |
|
|
|
|
 |
A.Pause,
G.Kukolj,
M.Bailey,
M.Brault,
F.Dô,
T.Halmos,
L.Lagacé,
R.Maurice,
M.Marquis,
G.McKercher,
C.Pellerin,
L.Pilote,
D.Thibeault,
and
D.Lamarre
(2003).
An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA.
|
| |
J Biol Chem,
278,
20374-20380.
|
 |
|
|
|
|
 |
D.Liu,
W.T.Windsor,
and
D.F.Wyss
(2003).
Double-stranded DNA-induced localized unfolding of HCV NS3 helicase subdomain 2.
|
| |
Protein Sci,
12,
2757-2767.
|
 |
|
|
|
|
 |
F.Narjes,
U.Koch,
and
C.Steinkühler
(2003).
Recent developments in the discovery of hepatitis C virus serine protease inhibitors--towards a new class of antiviral agents?
|
| |
Expert Opin Investig Drugs,
12,
153-163.
|
 |
|
|
|
|
 |
J.A.Grobler,
E.J.Markel,
J.F.Fay,
D.J.Graham,
A.L.Simcoe,
S.W.Ludmerer,
E.M.Murray,
G.Migliaccio,
and
O.A.Flores
(2003).
Identification of a key determinant of hepatitis C virus cell culture adaptation in domain II of NS3 helicase.
|
| |
J Biol Chem,
278,
16741-16746.
|
 |
|
|
|
|
 |
K.J.Blight,
J.A.McKeating,
J.Marcotrigiano,
and
C.M.Rice
(2003).
Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture.
|
| |
J Virol,
77,
3181-3190.
|
 |
|
|
|
|
 |
L.Vasiljeva,
A.Merits,
A.Golubtsov,
V.Sizemskaja,
L.Kääriäinen,
and
T.Ahola
(2003).
Regulation of the sequential processing of Semliki Forest virus replicase polyprotein.
|
| |
J Biol Chem,
278,
41636-41645.
|
 |
|
|
|
|
 |
M.P.Walker,
N.Yao,
and
Z.Hong
(2003).
Promising candidates for the treatment of chronic hepatitis C.
|
| |
Expert Opin Investig Drugs,
12,
1269-1280.
|
 |
|
|
|
|
 |
M.Wang,
K.K.Ng,
M.M.Cherney,
L.Chan,
C.G.Yannopoulos,
J.Bedard,
N.Morin,
N.Nguyen-Ba,
M.H.Alaoui-Ismaili,
R.C.Bethell,
and
M.N.James
(2003).
Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition.
|
| |
J Biol Chem,
278,
9489-9495.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.Casbarra,
F.D.Piaz,
P.Ingallinella,
S.Orrù,
P.Pucci,
A.Pessi,
and
E.Bianchi
(2002).
The effect of prime-site occupancy on the hepatitis C virus NS3 protease structure.
|
| |
Protein Sci,
11,
2102-2112.
|
 |
|
|
|
|
 |
B.M.Kümmerer,
and
C.M.Rice
(2002).
Mutations in the yellow fever virus nonstructural protein NS2A selectively block production of infectious particles.
|
| |
J Virol,
76,
4773-4784.
|
 |
|
|
|
|
 |
D.Moradpour,
V.Brass,
R.Gosert,
B.Wölk,
and
H.E.Blum
(2002).
Hepatitis C: molecular virology and antiviral targets.
|
| |
Trends Mol Med,
8,
476-482.
|
 |
|
|
|
|
 |
E.Bianchi,
and
A.Pessi
(2002).
Inhibiting viral proteases: challenges and opportunities.
|
| |
Biopolymers,
66,
101-114.
|
 |
|
|
|
|
 |
J.M.Caruthers,
and
D.B.McKay
(2002).
Helicase structure and mechanism.
|
| |
Curr Opin Struct Biol,
12,
123-133.
|
 |
|
|
|
|
 |
P.Ingallinella,
D.Fattori,
S.Altamura,
C.Steinkühler,
U.Koch,
D.Cicero,
R.Bazzo,
R.Cortese,
E.Bianchi,
and
A.Pessi
(2002).
Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus.
|
| |
Biochemistry,
41,
5483-5492.
|
 |
|
|
|
|
 |
P.S.Pang,
E.Jankowsky,
P.J.Planet,
and
A.M.Pyle
(2002).
The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding.
|
| |
EMBO J,
21,
1168-1176.
|
 |
|
|
|
|
 |
S.J.Archer,
D.M.Camac,
Z.J.Wu,
N.A.Farrow,
P.J.Domaille,
Z.R.Wasserman,
M.Bukhtiyarova,
C.Rizzo,
S.Jagannathan,
L.J.Mersinger,
and
C.A.Kettner
(2002).
Hepatitis C virus NS3 protease requires its NS4A cofactor peptide for optimal binding of a boronic acid inhibitor as shown by NMR.
|
| |
Chem Biol,
9,
79-92.
|
 |
|
|
|
|
 |
S.L.Tan,
A.Pause,
Y.Shi,
and
N.Sonenberg
(2002).
Hepatitis C therapeutics: current status and emerging strategies.
|
| |
Nat Rev Drug Discov,
1,
867-881.
|
 |
|
|
|
|
 |
A.Pessi
(2001).
A personal account of the role of peptide research in drug discovery: the case of hepatitis C.
|
| |
J Pept Sci,
7,
2.
|
 |
|
|
|
|
 |
B.W.Dymock
(2001).
Emerging therapies for hepatitis C virus infection.
|
| |
Expert Opin Emerg Drugs,
6,
13-42.
|
 |
|
|
|
|
 |
J.Schmidt-Mende,
E.Bieck,
T.Hugle,
F.Penin,
C.M.Rice,
H.E.Blum,
and
D.Moradpour
(2001).
Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase.
|
| |
J Biol Chem,
276,
44052-44063.
|
 |
|
|
|
|
 |
M.A.Walker
(2001).
Novel antiviral molecules.
|
| |
Drug Discov Today,
6,
747-749.
|
 |
|
|
|
|
 |
N.Butkiewicz,
N.Yao,
W.Zhong,
J.Wright-Minogue,
P.Ingravallo,
R.Zhang,
J.Durkin,
D.N.Standring,
B.M.Baroudy,
D.V.Sangar,
S.M.Lemon,
J.Y.Lau,
and
Z.Hong
(2000).
Virus-specific cofactor requirement and chimeric hepatitis C virus/GB virus B nonstructural protein 3.
|
| |
J Virol,
74,
4291-4301.
|
 |
|
|
|
|
 |
V.C.Lai,
W.Zhong,
A.Skelton,
P.Ingravallo,
V.Vassilev,
R.O.Donis,
Z.Hong,
and
J.Y.Lau
(2000).
Generation and characterization of a hepatitis C virus NS3 protease-dependent bovine viral diarrhea virus.
|
| |
J Virol,
74,
6339-6347.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |